Endocyte (West Lafayette, IN) a clinical-stage biopharmaceutical focused on folate-receptor targeted receptors in ovarian, NSCLC and breast cancers and renal cell carcinoma, closed a $26M Series B financing. Participants include Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $12M Series X financing bringing the total round to $45M. Participants include New Leaf Venture Partners, [...]

arGEN-X (The Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform and potential applications in oncology and infectious disease, closed a $13.8M Series A financing. Participants include Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund and Thuja Capital Healthcare.

NanoBio (Ann Arbor, MA) a clinical-stage company focused on topical antiinfectives and mucosal vaccines for the treatment and prevention of herpes labialis, onychomycosis, acne and cystic fibrosis closed a $10M Series B financing, bringing the total round to $22M. Participants include Perseus.

Avila Therapeutics (Waltham, MA) a preclinical-stage biopharmaceutical company focused on protein silencing drugs for viral infections, cancer and autoimmune diseases, closed a $30M Series B financing. Participants include Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.

Alios BioPharma (San Francisco, CA) a preclinical-stage small molecule and protein therapeutics company focused on viral disease via innate immune modulation, closed a $8M Series A financing bring the total round to $32M. Participants include SR One, Novo Ventures, Novartis Venture Fund and Roche Venture Fund.

Intrexon (Blacksburg, VA) a clinical-stage biopharmaceutical company focused on modular inducible cancer immunotherapeutics, closed a $10M Series C bring the total round financing to date of $35M. Participants include New River Management.

Zymeworks (Canada) a development-stage computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics, closed a $3.5M Series C financing. Participants include CTI Life Sciences Fund.

Sagent Pharmaceuticals (Schaumberg, Illinois) commercial-stage specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products, closed a $30M Series A financing, bringing the total round to $113M. Participants include Vivo Ventures.

Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $33M Series X financing. Participants inlcude Baker Brothers Investments, Tullis Health Investors, Four Partners, Yasuda Enterprise [...]

Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.

Molecular Templates (Austin, TX) a preclinical-stage company focused on a protein platform for the development of melanoma and other oncology therapeutics, closed a $2.5M Series A financing. Participants include Santé Ventures.

SFJ Pharmaceuticals (Pleasonton, CA) an entity designed to introduce approved drugs and Phase III candidates U.S. and European markets Japan, closed a $45M Series A financing. Participants include Abingworth Management and Clarus Ventures.